Aclarion reports strong growth and expanding clinical evidence base
1 report, 1 independent
Updated Oct 20
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Aclarion reported that its scan volumes grew 85% year-over-year in the third quarter of 2026, leading to 117% growth for the first nine months of 2026. The company also noted that peer-reviewed information supporting MRS as a viable alternative to provocative discography was published in the European Spine Journal. This growing evidence base is expected to support reimbursement initiatives in the United Kingdom and the United States.
From manilatimes.net
Why it matters
The expanding clinical evidence and commercial traction of Aclarion could be instrumental in securing broader reimbursement coverage for its services. This progress supports the push for increased market access in key regions like the United Kingdom.
From manilatimes.net